Prospective analysis of association between use of statins and melanoma risk in the Womens Health Initiative
Jagtap D et al. – There was no significant association between statin use and melanoma risk among postmenopausal women in the Women's Health Initiative (WHI).
The study population consisted of 119,726 postmenopausal white women, in which 1099 cases of malignant melanoma were identified over an average (±standard deviation) of 11.6±3.2years.
All diagnoses were confirmed by medical record review and pathology reports.
Information on statin use was collected at baseline and during follow-up.
Self-administered and interview-administered questionnaires were used to collect information on other risk factors.
Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs).
Analyses investigated the association of any statin use, type, potency, lipophilic status, and duration of use with melanoma.
Statins were used by 8824 women (7.4%) at baseline.
The annualized rate of melanoma was 0.09% among statin users and 0.09% among nonusers.
The multivariable adjusted HR for statin users compared with nonusers was 1.14 (95% CI, 0.91-1.43).
There were no significant differences in risk based on statin type, potency, category, duration, or in time-dependent models.